Context The contribution of blood extracellular vesicular (EV) programmed death-ligand 1
(PD-L1) and programmed death-1 (PD-1) in papillary thyroid cancer (PTC) is uncertain …

To date, no research evaluating the predictive capabilities of soluble programmed cell death-
ligand 1 (sPD-L1) in thyroid cancer patients has been performed. We aimed to investigate …

Background The immunotherapeutic role of programmed death-ligand 1 (PD-L1) in life
expectancy in many cancers has been highlighted. However, data regarding PD-L1 …

Background: Programmed death-ligand 1 (PD-L1) expression has been reported in several
malignancies, but the expression of PD-L1 in papillary thyroid cancer (PTC) has been …

Introduction PD-L1 is associated with prognosis and immunotherapeutic response in
patients with malignancies. In previous studies, PD-L1 expression was detected in many …

Background: Evidence has shown that programmed cell death ligand 1 (PD-L1)
overexpression is associated with poor prognosis and resistance to immune therapies in …

Abstract Programmed death-ligand 1 (PD-L1) expression on tumor cells is emerging as a
potential predictive biomarker in anti-PD-L1 directed cancer immunotherapy. We analyzed …

The expression of programmed death-ligand 1 (PD-L1) is an established prerequisite for the
administration of checkpoint inhibitor therapy and is of prognostic value in several cancer …

Background Programmed death‐ligand 1 (PD‐L1) expression is emerging as an important
predictive biomarker in anti–PD‐L1 cancer immunotherapy. Its role has been clearly defined …

Purpose The aim of this study was to elucidate the rates and prognostic roles of
programmed cell death ligand 1 (PD-L1) immunohistochemical (IHC) expression in various …